Table 2 White blood cell counts and leukocyte subset indices.

From: Inflammatory indices obtained from routine blood tests show an inflammatory state associated with disease progression in engineered stone silicosis patients

 

HC (22)

SS (53)

PMF (38)

P

Leukocytes*

6.3 ± 1.4

6.1 ± 1.7

6.4 ± 1.4

0.198a

Monocytes*

0.5 ± 0.1

0.56 ± 0.2

0.6 ± 0.2

0.012b

HC vs. SS; = nsc

HC vs. PMF; = 0.008c

SS vs. PMF; = 0.032c

Lymphocytes*

2.2 ± 0.6

1.7 ± 0.5

1.6 ± 0.4

0.001a

HC vs. SS; = 0.001d

HC vs. PMF; < 0.0001c

SS vs. PMF; = nsd

Neutrophils*

3.4 ± 0.9

3.7 ± 1.4

4 ± 1.2

0.071a

Platelets*

222.9 ± 40.6

239.8 ± 59.7

242.5 ± 40.6

0.334b

NLR

1.6 ± 0.5

2.4 ± 1

2.7 ± 1.5

 < 0.0001a

HC vs. SS; = 0.002d

HC vs. PMF; < 0.0001d

SS vs. PMF; = nsd

PLR

108.3 ± 37.1

154.5 ± 54.8

160.5 ± 53.5

 < 0.0001a

HC vs. SS; = 0.001c

HC vs. PMF; < 0.0001d

SS vs. PMF; nsd

LMR

4.5 ± 1.5

3.1 ± 0.9

2.7 ± 1

 < 0.0001a

HC vs. SS; < 0.0001c

HC vs. PMF; < 0.0001d

SS vs. PMF; = 0.044d

SII

369.5 ± 157

567.3 ± 290.7

668.9 ± 424.7

 < 0.0001a

HC vs. SS; = 0.002d

HC vs. PMF; < 0.0001d

SS vs. PMF; nsd

SIRI

0.8 ± 0.4

1.3 ± 0.7

1.8 ± 1.2

 < 0.0001a

HC vs. SS; = 0.002d

HC vs. PMF; < 0.0001d

SS vs. PMF; = 0.036d

AISI

191.5 ± 109.6

330.8 ± 219.8

447.1 ± 314.1

 < 0.0001a

HC vs. SS; = 0.006d

HC vs. PMF; < 0.0001d

SS vs. PMF; = 0.044d

  1. NLR (neutrophil/lymphocyte ratio), PLR (platelet/lymphocyte ratio), LMR (lymphocyte/monocyte ratio), SII (neutrophil x platelet/lymphocyte ratio), SIRI (neutrophil x monocyte/lymphocyte ratio) and AISI (neutrophil x monocyte x platelet/lymphocyte ratio). *(× 103 cell/µl). Data represent mean ± standard deviation. aKruskal–Wallis test, bANOVA, cStudent´s T-test, dMann–Whitney-U test. P, p value; ns non-significant.